Lexaria Bioscience Corp. SEC 10-Q Report

Lexaria Bioscience Corp., a biotechnology company specializing in drug delivery platforms, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational activities, highlighting significant progress in research and development, as well as ongoing challenges.

Financial Highlights

Revenue: $531,923, reflecting an increase of $151,645 compared to the same period last year, primarily due to higher licensing fees.

Gross Profit: $529,203, indicating a strong performance in managing cost of goods sold.

Net Loss: $(9,214,206), a significant increase from the previous year's loss of $(3,622,083), driven by higher research and development expenses.

Net Loss Attributable to Lexaria Shareholders: $(9,206,003), highlighting the company's ongoing investment in R&D and strategic initiatives.

Basic and Diluted Loss Per Share: $(0.53), compared to $(0.32) in the prior year, reflecting the increased net loss and share issuance.

Business Highlights

Revenue Segments: The company reported revenue from two main segments: IP Licensing and B2B Product. IP Licensing generated $522,000, while B2B Product sales amounted to $9,923 for the nine months ended May 31, 2025.

Research & Development Activities: Lexaria is advancing several R&D activities, focusing on DehydraTECH-powered GLP-1/GIP drugs and CBD for diabetes, weight loss, and hypertension. Key studies include a 12-week GLP-1 Diabetes Animal Study and a human pilot study comparing DehydraTECH-enhanced tirzepatide to Zepbound®.

Clinical Trials: The company is conducting a Phase 1b clinical study in Australia to investigate DehydraTECH formulations of cannabidiol and semaglutide, as well as tirzepatide, in overweight or obese, or pre- and Type II diabetic participants.

New Product Launches: Lexaria completed a human pilot study testing DehydraTECH-enhanced liraglutide against Saxenda®, showing a reduction in adverse events and similar efficacy in weight loss and blood glucose control.

Future Outlook: Lexaria plans to continue its R&D efforts, focusing on optimizing DehydraTECH formulations for GLP-1 drugs and advancing its DehydraTECH-CBD drug for hypertension. The company is also seeking pharmaceutical partners to support further development.

Operational Challenges: The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. It plans to address this through equity financing and potential strategic partnerships.

SEC Filing: Lexaria Bioscience Corp. [ LEXX ] - 10-Q - Jul. 14, 2025